Sign In
Buy DSNKY
$16.17
-0.190 (-1.16%)
At Close: Jun 02, 2026
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
01:30am, Thursday, 22'nd Jan 2026
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürg
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
08:00am, Wednesday, 21'st Jan 2026
Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines TORONTO, Jan. 21, 2026 /PRNewswire/ - Daiichi Sankyo (TSE: 4568) has further
Daiichi Sankyo Company, Limited (DSNKY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:45pm, Monday, 12'th Jan 2026
Daiichi Sankyo Company, Limited (DSNKY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
05:47am, Monday, 12'th Jan 2026
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 09'th Jan 2026
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
01:30am, Thursday, 08'th Jan 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
02:30am, Wednesday, 07'th Jan 2026
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe.
Financial Comparison: Daiichi Sankyo (OTCMKTS:DSNKY) vs. Sandoz Group (OTCMKTS:SDZNY)
02:00am, Wednesday, 07'th Jan 2026
Sandoz Group (OTCMKTS:SDZNY - Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) are both large-cap medical companies, but which is the better business? We will contrast the two com
Daiichi Sankyo (OTCMKTS:DSNKY) Shares Up 2.7% – Here’s Why
02:35am, Sunday, 28'th Dec 2025
Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) shares shot up 2.7% on Friday. The company traded as high as $21.99 and last traded at $21.99. 5,281 shares changed hands dur
CPRX vs. DSNKY: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 17'th Dec 2025
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript
US FDA approves Daiichi Sankyo's therapy to treat breast cancer
01:39pm, Monday, 15'th Dec 2025
The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line treatment of patients with a type of breast cancer, the regulator said o
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
09:00am, Monday, 15'th Dec 2025
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea , Dec. 15, 2
Daiichi Sankyo: Pressing The ADC Case Further, Not Being Felt By The Market
07:30am, Tuesday, 09'th Dec 2025
Daichi Sankyo remains a Buy, despite recent setbacks in its Trop2-directed ADC for lung cancer. DSKYF continues to advance its pipeline, offering positive catalysts over the next year. Recent financia
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new breast cancer clinical research across its DXd antibody drug conjugate (ADC) portfolio from more than 30 abstr
